Mantle Cell Lymphoma
📧 Sign up to get email alerts when something new happens for Mantle Cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-23Clinical Trial Update: Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma [Phase 1]
Phase 1 clinical trial evaluating Rituximab plus Bendamustine and ibrutinib (PCI-32765) in relapsed DLBCL, mantle cell lymphoma, and various…
-
CLINICAL_TRIALS research · 2026-03-23Clinical Trial Update: A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma [Phase 2]
A Phase 2 clinical trial update comparing three chemotherapy regimens for newly diagnosed mantle cell lymphoma, currently active/not recruit…
-
CLINICAL_TRIALS trial_result · 2026-03-23Clinical Trial Update: Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission [Phase 3]
Phase 3 trial evaluating whether adding autologous stem cell transplant to rituximab improves outcomes in patients with minimal residual dis…
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies [Phase 1]
Phase 1 study evaluating NX-2127 in adults with relapsed or refractory B-cell malignancies; currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-03-20Clinical Trial Update: ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A Phase 1/2 study evaluating ALX148 in combination with Rituximab and Lenalidomide for various B-cell non-Hodgkin lymphomas, with the trial …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma [Phase 2]
A Phase 2 clinical trial is evaluating ibrutinib in untreated high-risk smoldering mantle cell lymphoma; the study is currently active but n…
-
CLINICAL_TRIALS research · 2026-03-18Clinical Trial Update: Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom [Phase 2]
Phase 2 clinical trial update for CLR-131 in select B-cell malignancies, with expansion into Waldenström macroglobulinemia. The study status…
-
CLINICAL_TRIALS trial_result · 2026-03-17Clinical Trial Update: A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML [Phase 1]
Phase 1 trial update for voruciclib alone or with venetoclax in various B-cell malignancies and acute myeloid leukemia; the study has been t…
-
CLINICAL_TRIALS research · 2026-03-17Clinical Trial Update: A Study to Evaluate MTM-H-001 Injection in Adult Participants With Relapsed or Refractory B-cell Malignancies [NA]
This clinical trial update describes an evaluation of MTM-H-001 injection in adults with relapsed or refractory B-cell lymphomas, with the s…
-
CLINICAL_TRIALS trial_result · 2026-03-16Clinical Trial Update: Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy [Phase 2]
Phase 2 clinical trial evaluating a CD3xCD20 bispecific antibody for relapse/refractory B-cell non-Hodgkin lymphomas after CAR-T therapy has…
-
CLINICAL_TRIALS research · 2026-03-16Clinical Trial Update: CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma [Phase 1]
A Phase 1 clinical trial evaluating CD79b-19 CAR T cells for relapsed or refractory non-Hodgkin lymphoma, including several subtypes, is cur…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma [Phase 2]
Phase 2 clinical trial evaluating nemtabrutinib in combination with rituximab for mantle cell lymphoma is currently recruiting.
-
EMA approval · 2026-03-12EMA Authorised: Tecartus (autologous peripheral blood T cells CD4 and CD8 selected and CD3 and CD28 activated transduced with retroviral vector expressing anti-CD19 CD28/CD3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel)) — Kite Pharma EU B.V.
The European Medicines Agency authorised Tecartus (brexucabtagene autoleucel) for mantle cell lymphoma with conditional approval, and it has…
-
EMA approval · 2026-03-12EMA Authorised: Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto) (lenalidomide hydrochloride monohydrate) — Krka, d.d., Novo mesto
EMA authorised Lenalidomide Krka (lenalidomide hydrochloride monohydrate) for several hematologic malignancies, including multiple myeloma, …
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) [Phase 2]
This clinical trial update reports on a Phase 2 study of Zilovertamab Vedotin (MK-2140) as monotherapy and in combination for aggressive and…
-
CLINICAL_TRIALS trial_result · 2026-03-11Clinical Trial Update: Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas [Phase 1, Phase 2]
Phase 1/2 study evaluating the combination of lenalidomide with DA-EPOCH-R in MYC-associated B-cell lymphomas has completed, and results hav…
-
CLINICAL_TRIALS research · 2026-03-10Clinical Trial Update: Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma [Phase 2]
A Phase 2 clinical trial evaluating glofitamab in combination with lenalidomide is underway for high-risk patients with relapsed or refracto…
-
CLINICAL_TRIALS trial_result · 2026-03-05Clinical Trial Update: Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma [Phase 2]
Phase 2 trial evaluating ixazomib citrate with rituximab in indolent B-cell non-Hodgkin lymphoma has posted results.
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma [Phase 2]
This clinical trial update describes a Phase 2 study evaluating the combination of ibrutinib, a CD20 antibody, and venetoclax in patients wi…
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies [Phase 1]
A Phase 1 study evaluating feasibility and safety of collecting autologous hematopoietic stem cells and combining them with CAR T-cell thera…
-
CLINICAL_TRIALS research · 2026-03-03Clinical Trial Update: Study of Oral LOXO-338 in Patients With Advanced Blood Cancers [Phase 1]
Phase 1 study of oral LOXO-338 in advanced blood cancers is ongoing, with status listed as active but not recruiting.
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies [Phase 2]
Phase 2 clinical trial update describing a donor stem cell transplant conditioning regimen with treosulfan, fludarabine, and total-body irra…
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma [EARLY_Phase 1]
Clinical trial update describing a Phase 1 study of acalabrutinib plus rituximab followed by brexucabtagene autoleucel in previously untreat…
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study
A Mayo Clinic-sponsored clinical trial (HALT) is evaluating strategies to manage hypertension and prevent cardiovascular adverse events in p…
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma [Phase 1]
Phase 1 clinical trial from City of Hope evaluating CMV-specific CD19-CAR T-cells with CMV-MVA Triplex vaccine after stem cell transplantati…